Merck & Co., Inc.
145.27USD
-1.9700 (-1.34%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on MRK.
Valuation
P/E (TTM)
112.95x
P/E (Forward)
15.69x
EV/EBITDA
14.04x
EV/Revenue
6.09x
P/S (TTM)
5.38x
P/B
8.55x
FCF Yield
4.48%
Dividend Yield
2.34%
Gross Margin
72.97%
Operating Margin
-0.24%
Net Margin
4.77%
Peer Comparison — Drug Manufacturers - General
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | $358.41B | 112.95x | 14.04x | 4.48% | 5.07% | 2.34% |
| LLYEli Lilly and Company | $1.14T | 42.75x | 28.32x | 0.97% | 47.70% | 0.54% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $635.07B |
| 40.03x |
| 19.20x |
| 2.91% |
| 5.90% |
| 2.03% |
| ABBVAbbVie Inc. | $504.76B | 80.69x | 18.50x | 3.34% | 10.20% | 2.42% |
| NVSNovartis AG | $287.24B | 22.83x | 14.24x | 4.14% | 0.80% | 3.14% |
| AMGNAmgen Inc. | $237.48B | 27.28x | 16.26x | 3.64% | 9.50% | 2.29% |
| GILDGilead Sciences, Inc. | $193.48B | — | 14.71x | 5.05% | 10.20% | 2.10% |
| PFEPfizer Inc. | $171.16B | 39.00x | 8.79x | 7.29% | 2.60% | 5.73% |
| BMYBristol-Myers Squibb Company | $125.59B | 13.54x | 8.43x | 6.46% | 5.70% | 4.10% |